

1 **Title:** Germline predisposition to pediatric Ewing sarcoma is uniquely characterized by inherited
2 pathogenic variants in DNA damage repair genes

3

4 **AUTHORS/AFFILIATIONS**

Riaz Gillani	rngillani1@partners.org	1,2,3,4
Sabrina Y. Camp	scamp@broadinstitute.org	2,5
Seunghun Han	seunghun@broadinstitute.org	2,6
Jill K. Jones	jilljones@hms.harvard.edu	6
Schuyler O'Brien	wendeobrien@comcast.net	7
Erin L. Young	erin.olde@gmail.com	7
Lucy Hayes	lucy.hayes@hci.utah.edu	7
Gareth Mitchell	gareth.mitchell@hci.utah.edu	7
Trent Fowler	tfowler@peeltx.com	7
Alexander Gusev	alexander_gusev@dfci.harvard.edu	5,8
Junne Kamihara	junne_kamihara@dfci.harvard.edu	1,3,4
Katherine A. Janeway	katherine_janeway@dfci.harvard.edu	1,2,3,4
Joshua D. Schiffman	joshua.schiffman@hci.utah.edu	7
Brian D. Crompton	briand_crompton@dfci.harvard.edu	1,2,3,4,*
Saud H. AlDubayan	saud_aldubayan@dfci.harvard.edu	2,5,9,10,*
Eliezer M. Van Allen	eliezerm_vanallen@dfci.harvard.edu	2,5,11,*

5

6

7 **AUTHOR LIST FOOTNOTES**

- 8 1. Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
9 USA
- 10 2. Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
- 11 3. Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA
- 12 4. Boston Children's Hospital, Boston, MA 02115, USA
- 13 5. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115,
14 USA
- 15 6. Harvard Medical School, Boston, MA 02115, USA
- 16 7. Huntsman Cancer Institute, 2000 Circle of Hope Dr, Room 4246, Salt Lake City, UT
17 84112
- 18 8. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
19 Massachusetts, USA

- 20 9. Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115
21 10. College of Medicine, King Saudi bin Abdulaziz University for Health Sciences, Riyadh,
22 Saudi Arabia
23 11. Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA
24

25 *Corresponding authors

26 Brian D. Crompton
27 Dana-Farber Cancer Institute
28 450 Brookline Ave
29 Boston, MA 02215
30 Email: briand_crompton@dfci.harvard.edu
31 Phone: 617-632-3000
32

33 Saud H. AlDubayan
34 Dana-Farber Cancer Institute
35 450 Brookline Ave
36 Boston, MA 02215
37 Email: saud_aldubayan@dfci.harvard.edu
38 Phone: 617-632-3000
39

40 Eliezer M. Van Allen
41 Dana-Farber Cancer Institute
42 450 Brookline Ave
43 Boston, MA 02215
44 Email: eliezerm_vanallen@dfci.harvard.edu
45 Phone: 617-632-3000
46
47

48 **Abstract**

49 More knowledge is needed around the role and importance of specific genes in germline
50 predisposition to Ewing sarcoma to inform biological investigation and clinical practice. In this
51 study, we evaluated the enrichment of pathogenic germline variants in Ewing sarcoma relative
52 to other pediatric sarcoma subtypes, as well as patterns of inheritance of these variants. We
53 carried out an ancestry-matched case-control analysis to screen for enrichment of pathogenic
54 germline variants in 141 established cancer predisposition genes in 1138 individuals with
55 pediatric sarcoma diagnoses (222 Ewing sarcoma cases) relative to identically processed
56 cancer-free controls. Findings in Ewing sarcoma were validated with an additional cohort of 425
57 individuals, and 301 Ewing sarcoma parent-proband trios were analyzed for inheritance patterns
58 of identified pathogenic variants. A distinct pattern of pathogenic germline variants was seen in
59 Ewing sarcoma relative to other sarcoma subtypes. *FANCC* was the only gene with an
60 enrichment signal for heterozygous pathogenic variants in the discovery Ewing sarcoma cohort
61 (OR 14.4, 95% CI 3.5 – 51.2, $p = 0.002$, FDR = 0.28). This enrichment in *FANCC* heterozygous
62 pathogenic variants was seen again in the Ewing sarcoma validation cohort (OR 5.1, 95% CI
63 1.2 – 18.5, $p = 0.03$, single hypothesis), representing a broader importance of genes involved in
64 DNA damage repair, which were also nominally enriched in Ewing sarcoma cases. Pathogenic
65 variants in DNA damage repair genes were acquired through autosomal inheritance. Our study
66 provides new insight into germline risk factors contributing to Ewing sarcoma pathogenesis.

67

68 **Introduction**

69 Ewing sarcoma is the second most common bone and soft tissue cancer impacting
70 children and adolescents worldwide¹. It is an aggressive malignancy that is metastatic in 25% of
71 cases at presentation and requires a very intensive treatment regimen including multiple
72 chemotherapies, as well as surgery or radiation for local control. While overall survival for
73 localized disease has improved to 75%, treatment confers significant morbidity, and cure rates

74 for metastatic and relapsed disease remain poor². Through a better understanding of the
75 predisposing genetic factors contributing to Ewing sarcoma pathogenesis, the pediatric
76 oncology community would be able to develop more informed and less toxic treatment
77 regimens, as well as better screen children at risk for disease, opening the door to opportunities
78 for earlier detection and even prevention.

79 Ewing sarcoma is driven by *EWSR1-ETS* gene fusions^{1,3}, and is often characterized by
80 a complex rearrangement pattern known as chromoplexy⁴. The genetic events preceding these
81 simple and complex rearrangements remain largely unknown. Prior work has suggested a role
82 for pathogenic germline variants in DNA damage repair (DDR) genes in Ewing sarcoma, but
83 systematic case-control analyses to precisely define this role have not been undertaken^{5,6}.
84 Much of what is known about germline predisposition to Ewing sarcoma has centered on
85 common population variants identified as susceptibility loci from genome-wide association
86 studies (GWAS)^{1,7-9}, and a comprehensive evaluation of the relative contribution of rare coding
87 pathogenic germline variants is largely incomplete.

88 Furthermore, a more complete understanding of the familial inheritance patterns of
89 genetic risk factors in Ewing sarcoma is needed to guide cascade testing strategies with broad
90 potential clinical impact. While guidelines for familial testing have been developed for various
91 cancer predisposition syndromes^{10,11}, patients with Ewing sarcoma and family members are not
92 uniformly referred for genetic testing. Case reports of siblings with metachronous Ewing
93 sarcoma diagnoses have suggested that germline variants shared within families may increase
94 risk, but these have not yet been identified¹². Family-based germline sequencing, such as the
95 analysis of parent-proband trios, is thus a powerful tool for better understanding the inheritance
96 of pathogenic germline variants in pediatric sarcoma generally, and Ewing sarcoma in
97 particular¹³.

98 We hypothesized that through a systematic comparative analysis of germline
99 predisposition across pediatric sarcoma subtypes, we would elucidate distinct patterns of rare

100 coding pathogenic variants in Ewing sarcoma. We therefore undertook a three-stage study
101 comprising 1) an ancestry-matched case-control analysis utilizing a discovery pan-sarcoma
102 cohort, 2) validation with an ancestry-matched case-control analysis of an additional cohort of
103 patients with Ewing sarcoma, and 3) evaluation of inheritance in germline variants for patients
104 with Ewing sarcoma and their parents.

105

106 **Materials and Methods**

107 ***Ethics Approval and Consent to Participate***

108 Written informed consent from patients and institutional review board approval, allowing
109 comprehensive genetic analysis of germline samples, were obtained by the original studies that
110 enrolled patients. The secondary genomic and deep-learning analyses performed for this study
111 were approved under Dana-Farber Cancer Institute institutional review board protocols 21-143
112 and 20-691. This study conforms to the Declaration of Helsinki.

113 ***Study Participants***

114 A total of 1138 individuals with pediatric sarcoma diagnoses were included in the
115 discovery cohort (Supplemental Methods). A combination of germline whole-genome
116 sequencing (WGS) and whole-exome sequencing (WES) was aggregated for these individuals
117 across four data sources; WGS was converted to WES equivalents using predefined target
118 intervals to focus on coding variants only (Supplemental Methods). For validation, germline
119 WGS for 425 individuals with Ewing sarcoma from the Gabriella Miller Kids First (GMKF)
120 program was utilized. For 301 individuals with Ewing sarcoma from GMKF, germline WGS for
121 parents was available (602 parents) and used for analysis of inheritance among trios (Tables S1
122 and S2; Supplemental Methods). Sequenced exomes for 24128 cancer-free individuals from six
123 cohorts were extensively quality controlled, identically processed, and analyzed in the same
124 way as cases for use as controls in this study (Supplemental Methods).

125 ***Population Stratification***

126 Principal component analysis (PCA) was undertaken utilizing germline genotypes for all
127 discovery, validation, and control cohorts to enable ancestry inference. We used a trained
128 random forest classifier to assign one of the five 1000 Genomes defined super populations
129 (European, African, Admixed American, East Asian, and South Asian) to each sample in our
130 case and control cohorts. Cases and controls were matched on genetic ancestry composition
131 based on the first ten principal components from the preceding analysis (Supplemental
132 Methods).

133 **Germline Variant Characterization**

134 We called germline variants with a deep learning method, DeepVariant, which has
135 shown superior sensitivity and specificity compared with a joint genotyping-based approach
136 (version 0.8.0)^{14,15}. High-quality coding variants were utilized for subsequent analyses
137 (Supplemental Methods).

138 **Gene Sets**

139 We evaluated the prevalence of pathogenic variants in a list of established germline
140 cancer predisposition genes (n = 141; Table S3)¹⁶⁻¹⁹. A subset of these genes had an
141 established role in DDR (n = 43). The low-penetrance founder *CHEK2* variant (p.Ile200Thr) was
142 considered separately from other *CHEK2* pathogenic variants. We also evaluated predefined
143 and non-mutually exclusive functional subsets of the DDR gene list for pathway-based
144 enrichment analysis, curated through evaluation of known primary biological function in the
145 Online Mendelian Inheritance in Man (OMIM)²⁰ and Reactome²¹ databases: mismatch repair (n
146 = 4), Fanconi Anemia (n = 16), double-strand break repair (n = 12), and nucleotide excision
147 repair (n = 6).

148 **Germline Variant Pathogenicity Evaluation**

149 Based on ClinVar database and Variant Effect Predictor (VEP) consequence
150 annotations, all detected germline variants in cancer predisposition genes were classified into
151 five categories: benign, likely benign, variants of unknown significance, likely pathogenic, and

152 pathogenic using the American College of Medical Genetics (ACMG) guidelines²². Only putative
153 loss-of-function, pathogenic, and likely pathogenic variants were included in this study (hereafter
154 collectively referred to as pathogenic variants). Pathogenic variants were manually evaluated
155 using the raw genomic data and the Integrative Genomics Viewer (IGV; Supplemental Methods;
156 Tables S4, S5, and S6)^{23,24}.

157 **Outcomes**

158 The primary outcomes included gene-level enrichment analysis of germline pathogenic
159 variants in individuals with Ewing sarcoma compared to other pediatric sarcomas, validation of
160 enrichment findings in Ewing sarcoma, and analysis of mechanisms of inheritance among
161 germline pathogenic variants in Ewing sarcoma. The secondary outcomes included exploratory
162 gene and pathway level enrichment analysis of germline pathogenic variants in DDR genes in
163 Ewing sarcoma.

164 **Statistical Analysis**

165 Two-sided Fisher's exact tests were used to calculate the odds ratios, 95% confidence
166 intervals (CIs), and P values of germline pathogenic variant enrichment in affected versus
167 unaffected cohorts for each of the examined cancer predisposition genes. $P < 0.05$ was the
168 threshold for nominal enrichment signal. For the discovery cohort, the false discovery rate
169 (FDR) was calculated using the Benjamini-Hochberg procedure; $FDR < 0.05$ was used as the
170 threshold for enrichment meeting multiple hypothesis testing criteria for validation in the
171 absence of a secondary cohort (applied to the discovery cohort; Supplemental Methods).

172

173 **Results**

174 ***Study overview and characteristics of discovery and validation cohorts***

175 Our discovery cohort of 1138 primarily pediatric patients with sarcoma comprised
176 osteosarcoma (436 cases), rhabdomyosarcoma (180 cases), Ewing sarcoma (222 cases), and
177 other subtypes (300 cases; Figure 1A). The mean age of patients in the discovery cohort was

178 10.8 years (SD 5.5 years), and 52% of patients were male (Figure 1B). Our validation cohort
179 comprised 433 patients with Ewing sarcoma; of these, 425 cases were available for an
180 ancestry-matched case-control study, and 301 cases were available as parent-proband trios for
181 evaluation for mechanisms of inheritance (Figure 1A). The mean age of patients in the Ewing
182 sarcoma validation cohort was 13.3 years (SD 6.6 years), and 54% of patients were male
183 (Figure 1C). The germline exome-wide mean target coverage for the discovery cohort samples
184 was 53.9X (interquartile range [IQR] 37.6 – 66.3X), and for the Ewing sarcoma validation cohort
185 samples was 27.3X (IQR 24.6 – 30.2X); exome-wide variant call rates were satisfactory for all
186 samples (Figure S1). Differential coverage for evaluated genes was assessed, and overall
187 comparable between cases and controls (Figure S2). All samples had satisfactory indel rates,
188 variant transition-to-transversion rates, and genotype quality (Figure S3).

189

190 ***Pathogenic germline variants in cancer predisposition genes are enriched across***
191 ***pediatric sarcoma histologic subtypes relative to cancer-free controls***

192 We assessed the frequency of pathogenic germline variants in 141 established cancer
193 predisposition genes in our discovery cohort^{16–19}. Our discovery cohort had broad representation
194 from five major continental ancestries (Figure 2A; Figure S4); control cohorts for comparison
195 were identically processed and ancestry-matched. The presence of pathogenic germline
196 variants was not significantly associated with age (mean 10.9 vs. 10.5 years, $p = 0.42$ by two-
197 sided t-test) or sex ($p = 0.81$ by Fisher's exact test). Across the pan-sarcoma discovery cohort,
198 nominal enrichment signal at $p < 0.05$ was observed for multiple genes previously implicated in
199 sarcoma pathogenesis, including *TP53*, *NF1*, and *DICER1*^{5,18,25}; nominal enrichment signal was
200 also seen for *MUTYH*, *PALB2*, *NTHL1*, and *FANCC*, genes with less prior supporting evidence
201 for their role in sarcoma germline predisposition. The enrichment in *TP53* was greatest,
202 reaching significance at $FDR < 0.05$ across the pan-sarcoma discovery cohort (Figure 2B; Table
203 S7).

204 We next carried out ancestry-matched enrichment analyses for each of the three major
205 sarcoma histologic subtypes. For osteosarcoma, nominal enrichment signal was observed for 5
206 genes (Table S8). These included *TP53* and *RB1*, previously validated as important in germline
207 predisposition to osteosarcoma (Figure 2C)²⁶; once again, only *TP53* reached significance at
208 FDR < 0.05. *RECQL* also had nominal enrichment signal in osteosarcoma cases relative to
209 controls; however, due to relative underpowering, the previously implicated predisposition gene
210 *RECQL4* did not, despite a higher absolute frequency in cases relative to controls (Figure S5).
211 Nominal enrichment signal was also observed for *MUTYH* and *FANCM*, genes without
212 substantial prior evidence supporting their role in germline predisposition to osteosarcoma²⁷.

213 In rhabdomyosarcoma, nominal enrichment signal was observed for *TP53*, *NF1*, and
214 *DICER1*, genes that have previously been implicated in germline predisposition to pediatric
215 rhabdomyosarcoma²⁸. We were able to redemonstrate a nominal enrichment signal for *BRCA2*
216 and *CHEK2*, genes with a previous moderate level of evidence for a role in germline
217 predisposition to rhabdomyosarcoma^{25,29-31}. No genes reached significance at FDR < 0.05
218 (Figure 2D; Table S9).

219 In Ewing sarcoma, the only gene with nominal enrichment signal was *FANCC*, with
220 heterozygous pathogenic variants seen in 3 out of 222 cases (1.3%, OR 14.4, 95% CI 3.5 –
221 51.2, p = 0.002, FDR = 0.28; Figure 2E; Figure S5; Table S10). Prior work had shown a general
222 association between germline variants in Fanconi Anemia pathway genes and translocation-
223 driven sarcomas, but the role of *FANCC* in germline predisposition to Ewing sarcoma had not
224 previously been reported to our knowledge⁵. In contrast to osteosarcoma and
225 rhabdomyosarcoma, no pathogenic germline *TP53* variants were observed in Ewing sarcoma.

226 Thus, our enrichment analysis of pathogenic variants in our discovery cohort
227 demonstrated a unique pattern of predisposing variants across pediatric sarcoma subtypes, with
228 a strong enrichment signal for *TP53* in all sarcoma subtypes except Ewing sarcoma. Having
229 demonstrated a distinct enrichment pattern among Ewing sarcoma cases relative to

230 osteosarcoma and rhabdomyosarcoma, we proceeded to evaluate the enrichment signal in
231 *FANCC* in our larger validation cohort of Ewing sarcoma cases.

232

233 ***FANCC and other DNA damage repair genes harbor pathogenic germline variants in***
234 ***Ewing sarcoma***

235 Our validation cohort of Ewing sarcoma patients was also ancestry-matched to cancer-
236 free controls to enable targeted evaluation of *FANCC* enrichment (Figure S6). Heterozygous
237 pathogenic germline *FANCC* variants were again enriched, seen in 3 of 425 cases (0.7%, OR
238 5.1, 95% CI 1.2 – 18.5, $p = 0.03$, single hypothesis; Figure 3A). The pooled odds ratio for
239 *FANCC* enrichment between discovery and validation cohorts remained significant (6 of 647
240 cases, 0.9%, OR 7.7, 95% CI 3.1 – 19.3, $p < .0001$).

241 Prior mechanistic work has demonstrated that *FANCC* knockout contributes to
242 rearrangement signatures consistent with homologous recombination deficiency³². We thus
243 asked whether the recurrent enrichment of *FANCC* represented a broader importance of DDR
244 genes in germline predisposition to Ewing sarcoma, as has been previously suggested⁶. We
245 performed an exploratory analysis in the Ewing sarcoma validation cohort on the subset of 43
246 cancer predisposition genes with specific DDR pathway roles. In aggregate, pathogenic variants
247 in DNA double-strand break repair (DSB) genes (OR 1.8, 95% CI 1.1 – 3.0, $p = 0.02$) and
248 nucleotide excision repair genes (OR 2.8, 95% CI 1.2 – 5.9, $p = 0.01$; Figure 3B, Table S11)
249 were enriched. While the discovery Ewing sarcoma and rhabdomyosarcoma cohorts were
250 underpowered for a comparative pathway analysis (Tables S12 and S13), the discovery
251 osteosarcoma cohort was of comparable size. In aggregate, DDR genes were enriched in
252 discovery osteosarcoma cases (OR 1.9, 95% CI 1.4 – 2.6, $p = 0.0001$, Figure S7); notably and
253 in contrast to Ewing sarcoma, this was driven largely by germline *TP53* mutations, as the DSB
254 and nucleotide excision repair pathways were not significantly enriched (Table S14). In the
255 validation cohort of patients with Ewing sarcoma, the presence of pathogenic germline variants

256 in DDR genes was not significantly associated with age (mean 13.3 vs. 13.5 years, $p = 0.88$ by
257 two-sided t-test) or sex ($p = 0.10$ by Fisher's exact test).

258 In evaluating the specific genes contributing to the collective enrichment of the DSB and
259 nucleotide excision repair pathways, we found that *CHEK2*, *ERCC2*, and *ERCC4* had nominal
260 enrichment signal at $p < 0.05$ in our validation Ewing sarcoma cohort, although none of these
261 individual genes reached significance at $FDR < 0.05$ when correcting for 43 DDR genes (Table
262 S15). In combination with *FANCC*, these four genes harbored germline pathogenic variants in
263 16 of 425 Ewing sarcoma cases (3.8%), compared with 60 of 7259 controls (0.8%; Figure 3C).

264 Similar to our discovery Ewing sarcoma cohort, we once again identified no pathogenic
265 germline *TP53* variants in our validation Ewing sarcoma cohort. The rate of pathogenic germline
266 *TP53* variants in patients with Ewing sarcoma (0%) was significantly lower than that seen for all
267 sarcomas in aggregate (1.6%, $p = 0.006$ by Fisher's exact test), and osteosarcoma in particular
268 (2.8%, $p = 0.0005$ by Fisher's exact test; Figure 3D). This, in combination with the recurrent
269 enrichment of pathogenic germline mutations in *FANCC*, as well as the collective enrichment of
270 DSB and nucleotide excision repair pathways, demonstrated a distinct pattern of germline
271 mutations in Ewing sarcoma relative to other pediatric sarcoma subtypes.

272

273 ***Pathogenic germline variants in DNA damage repair genes are inherited in high-risk*** 274 ***families***

275 Having identified pathogenic germline mutations in *FANCC* and other DDR genes in
276 Ewing sarcoma, we next sought to assess inheritance of these variants. Thus, we evaluated the
277 301 patients with Ewing sarcoma from our validation cohort that were part of parent-proband
278 sequencing trios. Among these 301 patients, 32 harbored pathogenic germline variants in DDR
279 genes (10.6%; Figure 4A). In 32 of 32 probands in which a pathogenic germline DDR variant
280 was identified in a proband, the same germline DDR variant was identified in one of the parents
281 (100%). In contrast, for probands in whom a pathogenic germline DDR variant was not

282 identified, only 19 of 269 had at least one parent with a germline DDR variant (7.1%; Figure 4B).
283 Collectively, pathogenic variants in DSB repair genes were more common among parents of
284 probands than ancestry-matched cancer-free controls (OR 1.8, 95% CI 1.2 – 2.7, $p = 0.006$).
285 While pathogenic germline variants in genes such as *BRCA2* and *CHEK2* were also observed in
286 some parents and not inherited by probands, these were at a rate that was comparable to the
287 population frequency (Figure S8).

288 Identical pathogenic germline DDR variants in probands and parents impacted *FANCC*,
289 *ERCC2*, *CHEK2*, and *BRCA1* among other genes (Figure 4C). In three instances, heterozygous
290 germline pathogenic variants affecting multiple DDR genes were seen in probands, with each
291 variant also identified in a parent (Figure 4D).

292 We sought to understand whether as yet unidentified *de novo* pathogenic variants in
293 other coding genes may coordinate with or complement the inherited DDR variants to explain a
294 significant proportion of the unexplained germline risk for developing pediatric Ewing sarcoma.
295 Based on prior frameworks^{33–35}, we reasoned that finding pathogenic *de novo* variants
296 recurrently impacting the same gene in a cohort of 301 proband-parent trios would be highly
297 unlikely by chance, implicating potential additional candidate risk genes. However, in our cohort,
298 we identified recurrent pathogenic *de novo* germline variants in only one gene, *TTN*, which
299 occurred in two separate Ewing sarcoma cases. As the frequency of pathogenic germline
300 variants in *TTN* between cases and cancer-free controls was not significantly different and there
301 is no established biological role for *TTN* in Ewing sarcoma oncogenesis, there was insufficient
302 evidence to support its role in germline predisposition to Ewing sarcoma (Figure S9).

303 Taken together, pathogenic germline variants in DSB genes were present more
304 frequently in families of patients with Ewing sarcoma relative to cancer-free controls. Autosomal
305 inheritance, as opposed to *de novo* development, was the mechanism of inheritance of these
306 moderate penetrance risk variants.

307

308 Discussion

309 This study represents the largest and most systematic analysis of germline
310 predisposition to Ewing sarcoma relative to other pediatric sarcoma subtypes to date. Having
311 assembled germline sequencing data from 1138 patients with pediatric sarcoma diagnoses, we
312 undertook rigorous ancestry-matched case-control analyses and illustrated distinct patterns of
313 enrichment amongst pathogenic variants in Ewing sarcoma relative to osteosarcoma and
314 rhabdomyosarcoma. Supporting the validity of our approach, we were able to recover
315 enrichment signal in many cancer predisposition genes known to be associated with pediatric
316 sarcoma risk, such as *TP53*, *RB1*, and *DICER1*. We additionally demonstrated enrichment
317 signal in several cancer predisposition genes with less well-characterized links to pediatric
318 sarcoma, most notably *FANCC* in Ewing sarcoma. We then validated the enrichment of
319 pathogenic germline variants in *FANCC* among patients with Ewing sarcoma using an
320 independent cohort of 425 unique patients. This recurrent enrichment of heterozygous
321 pathogenic germline variants in *FANCC* provides evidence for its role in increasing risk for some
322 cases of Ewing sarcoma, and raises the possibility that monoallelic germline variants in Fanconi
323 anemia genes may confer increased risk in other translocation-associated cancers.

324 We demonstrated that the enrichment in *FANCC* pathogenic germline variants
325 represented a broader importance of DNA damage repair (DDR) genes, and both the DNA
326 double-strand break (DSB) and nucleotide excision repair pathways in particular, for Ewing
327 sarcoma germline predisposition. While prior studies have identified occasional instances of
328 pathogenic germline *TP53* variants amongst cases of Ewing sarcoma, through comparative
329 analyses, we found that the frequency of pathogenic germline *TP53* variants among cases of
330 Ewing sarcoma was significantly lower in relation to other pediatric sarcoma subtypes^{6,29}. This
331 finding is supported by the clinical observation that Ewing sarcoma is not frequently seen in
332 families with Li-Fraumeni syndrome³⁶.

333 Using parent-proband trios, we showed that pathogenic germline variants in DNA
334 damage repair genes found in patients with Ewing sarcoma are also present in their parents,
335 and therefore passed on through autosomal inheritance. We found pathogenic germline variants
336 in DSB genes enriched amongst parents of patients with Ewing sarcoma. As moderate
337 penetrance risk variants that are also present in parents, we reasoned that pathogenic germline
338 variants in DDR genes play a substantial role in increasing risk for developing Ewing sarcoma,
339 but are likely not sufficient to cause the disease in isolation. However, we did not identify *de*
340 *novo* variants recurrently impacting other genes to support a role for their interaction with
341 pathogenic germline variants in DDR genes to promote germline predisposition to Ewing
342 sarcoma.

343 Our study had some notable limitations. While pathogenic germline variants in *FANCC*
344 occurred at a rate greater than expected by chance in cases of Ewing sarcoma, the overall
345 frequency of these variants was low (1.3% in the discovery cohort, 0.7% in the validation
346 cohort), supporting the role of *FANCC* as a moderate penetrance cancer predisposition gene as
347 opposed to the sole driver of disease pathogenesis. Additionally, our focus on germline variants
348 in select DDR genes within Ewing sarcoma likely underestimated the total contribution of rare
349 coding pathogenic germline variants to Ewing sarcoma pathogenesis. Finally, similar to much
350 preceding work in germline predisposition in pediatric cancers, our methods were limited to
351 identifying known pathogenic germline SNVs/ indels conferring increased risk in pediatric
352 sarcoma. As progress is made in germline structural variant discovery³⁷ and placing rare
353 pathogenic variants in the context of complex germline interactions³⁸⁻⁴¹, future studies and new
354 statistical frameworks will be needed to more completely define the role of germline
355 predisposition in Ewing sarcoma pathogenesis.

356 Taken together, our analysis supports a unique contribution of germline variants in
357 *FANCC* and other DDR genes to Ewing sarcoma pathogenesis. Our study provides a

358 foundation to inform approaches to genetic testing for patients with Ewing sarcoma, as well as
359 cascade testing for family members.

360

361 **Acknowledgments**

362 This work was supported by a Research Training Grant in Pediatric Oncology NIH
363 5T32CA136432-12 (R.G.), American Society of Clinical Oncology Conquer Cancer – Sarcoma
364 Foundation of America Young Investigator Award (R.G.), Jay Vernon Jackson Memorial
365 Research Award from Sarcoma Foundation of America (R.G.), Edward B. Clark, MD Endowed
366 Chair in Pediatric Research (J.D.S.), Helen Clise Presidential Endowed Chair in Li-Fraumeni
367 Syndrome Research (J.D.S.), Conquer Cancer Foundation Career Development Award 13167
368 from the American Society of Clinical Oncology (S.H.A.), Young Investigator Award 18YOUN02
369 from the Prostate Cancer Foundation (S.H.A.), Physician Research Award
370 (PC200150/W81XWH-21-1-0084) of the Department of Defense (S.H.A), NIH R37 CA222574
371 (E.M.V.A.), R01 CA227388 (E.M.V.A.), U01 CA233100 (E.M.V.A.), Innovation in Cancer
372 Informatics Award (E.M.V.A.), COG Biospecimen Bank Grant U24CA196173, NCTN Operations
373 Center Grant U10CA180886, NCTN Statistics & Data Center Grant U10CA180899, and
374 Gabriella Miller Kids First 1X01 HL 140547-01.

375

376 **Declaration of interests**

377 R.G. has equity in Google, Microsoft, Amazon, Moderna, Pfizer, and Vertex
378 Pharmaceuticals. E.M.V.A. holds consulting roles with Tango Therapeutics, Invitae, Genome
379 Medical, Enara Bio, Janssen, and Manifold Bio; he receives research support from Bristol-Myers
380 Squibb and Novartis; he has equity in Tango Therapeutics, Genome Medical, Syapse, Enara
381 Bio, Manifold Bio, and Microsoft; he has received travel reimbursement from Roche and
382 Genentech; and he has filed institutional patents on chromatin mutations, immunotherapy
383 response, and methods for clinical interpretation. Other authors have no relevant disclosures.

384

385 **Data and code availability**

386 Sequencing data analyzed in this study were obtained from multiple publicly accessible
387 data repositories. Sequenced samples from the discovery cohort came from four data sources:
388 St. Jude Cloud (Pediatric Cancer Genome Project, St. Jude Lifetime, Genomes for Kids, and
389 Childhood Cancer Survivor Study; n = 1033)⁴²⁻⁴⁶, dbGaP study “Genomic Sequencing of Ewing
390 Sarcoma” (phs000804.v1.p1; n = 26)^{47,48}, dbGaP study “Osteosarcoma Genomics”
391 (phs000699.v1.p1, n = 58)⁴⁹, and ICGC study “Bone Cancer – UK” (BOCA-UK, n = 63)⁵⁰.
392 Sequenced samples from the Ewing sarcoma validation and trio cohorts were from the Gabriella
393 Miller Kids First “Ewing Sarcoma – Genetic Risk” study (phs001228.v1.p1)⁵¹. The control
394 cohorts came from the following sources: Autism Sequencing Consortium (dbGaP phs000298),
395 Framingham Cohort (dbGaP phs000007), Multi-Ethnic Study of Atherosclerosis (dbGaP
396 phs000209), Lung Cohort (dbGaP phs000291), in-house collection of exomes from National
397 Heart, Lung, and Blood Institute “Grand Opportunity” Exome Sequencing Project (NHLBI GO-
398 ESP), and the 1000 Genomes Project⁵².

399

400 **Supplemental data**

401 Supplemental data includes supplemental methods, 9 supplemental figures, and 15
402 supplemental tables.

403

404 **Author contributions**

405 R.G., E.M.V.A., and S.H.A. conceived the project design, carried out the analysis, and
406 wrote the manuscript. B.D.C. and K.A.J. contributed to refinement of the project design, data
407 interpretation, validation of findings, and manuscript review. S.Y.C., S.A., and J.K.J. provided
408 support with data analysis, data interpretation, and manuscript review. J.D.C. contributed to
409 validation of findings, data interpretation, and manuscript review. E.Y., S.O., L.H., G.M., and

410 T.F. carried out foundational work that enabled validation of findings. J.K. and A.G. contributed
411 to data interpretation and manuscript review.

412

413 **Disclaimer**

414 The content is solely the responsibility of the authors and does not necessarily represent
415 the official views of the National Institutes of Health.

416

417 **References**

- 418 1. Grünewald, T.G.P., Cidre-Aranaz, F., Surdez, D., Tomazou, E.M., De Álava, E., Kovar, H.,
419 Sorensen, P.H., Delattre, O., and Dirksen, U. (2018). Ewing sarcoma. *Nat. Rev. Dis. Prim.* *4*,.
- 420 2. Balamuth, N.J., and Womer, R.B. (2010). Ewing's sarcoma. *Lancet Oncol.* *11*, 184–192.
- 421 3. Brohl, A.S., Solomon, D.A., Chang, W., Wang, J., Song, Y., Sindiri, S., Patidar, R., Hurd, L.,
422 Chen, L., Shern, J.F., et al. (2014). The Genomic Landscape of the Ewing Sarcoma Family of
423 Tumors Reveals Recurrent STAG2 Mutation. *10*,.
- 424 4. Anderson, N.D., De Borja, R., Young, M.D., Fuligni, F., Rosic, A., Roberts, N.D., Hajjar, S.,
425 Layeghifard, M., Novokmet, A., Kowalski, P.E., et al. (2018). Rearrangement bursts generate
426 canonical gene fusions in bone and soft tissue tumors. *Science (80-.)*. *361*,.
- 427 5. Ballinger, M.L., Goode, D.L., Ray-Coquard, I., James, P.A., Mitchell, G., Niedermayr, E., Puri,
428 A., Schiffman, J.D., Dite, G.S., Cipponi, A., et al. (2016). Monogenic and polygenic determinants
429 of sarcoma risk: an international genetic study. *Lancet Oncol.* *17*, 1261–1271.
- 430 6. Brohl, A.S., Patidar, R., Turner, C.E., Wen, X., Song, Y.K., Wei, J.S., Calzone, K.A., and
431 Khan, J. (2017). Frequent inactivating germline mutations in DNA repair genes in patients with
432 Ewing sarcoma. *Genet. Med.* *19*, 955–958.
- 433 7. Grünewald, T.G.P., Bernard, V., Gilardi-Hebenstreit, P., Raynal, V., Surdez, D., Aynaud,
434 M.M., Mirabeau, O., Cidre-Aranaz, F., Tirode, F., Zaidi, S., et al. (2015). Chimeric EWSR1-FLI1
435 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nat. Genet.*

- 436 47, 1073–1078.
- 437 8. Postel-Vinay, S., Véron, A.S., Tirode, F., Pierron, G., Reynaud, S., Kovar, H., Oberlin, O.,
438 Lapouble, E., Ballet, S., Lucchesi, C., et al. (2012). Common variants near TARDBP and EGR2
439 are associated with susceptibility to Ewing sarcoma. *Nat. Genet.* *44*, 323–327.
- 440 9. Machiela, M.J., Grünewald, T.G.P., Surdez, D., Reynaud, S., Mirabeau, O., Karlins, E.,
441 Rubio, R.A., Zaidi, S., Grossetete-Lalami, S., Ballet, S., et al. (2018). Genome-wide association
442 study identifies multiple new loci associated with Ewing sarcoma susceptibility. *Nat. Commun.* *9*,
443 1–8.
- 444 10. Kratz, C.P., Achatz, M.I., Brugieres, L., Frebourg, T., Garber, J.E., Greer, M.L.C., Hansford,
445 J.R., Janeway, K.A., Kohlmann, W.K., McGee, R., et al. (2017). Cancer screening
446 recommendations for individuals with Li-Fraumeni syndrome. *Clin. Cancer Res.* *23*, e38–e45.
- 447 11. Schultz, K.A.P., Williams, G.M., Kamihara, J., Stewart, D.R., Harris, A.K., Bauer, A.J.,
448 Turner, J., Shah, R., Schneider, K., Schneider, K.W., et al. (2018). Dicer1 and associated
449 conditions: Identification of at-risk individuals and recommended surveillance strategies. *Clin.*
450 *Cancer Res.* *24*, 2251–2261.
- 451 12. Joyce, M.J., Harmon, D.C., Mankin, H.J., Suit, H.D., Schiller, A.L., and Truman, J.T. (1984).
452 Ewing's sarcoma in female siblings: A clinical report and review of the literature. *Cancer* *53*,
453 1959–1962.
- 454 13. Kuhlen, M., Taeubner, J., Brozou, T., Wiczorek, D., Siebert, R., and Borkhardt, A. (2019).
455 Family-based germline sequencing in children with cancer. *Oncogene* *38*, 1367–1380.
- 456 14. Poplin, R., Chang, P.C., Alexander, D., Schwartz, S., Colthurst, T., Ku, A., Newburger, D.,
457 Dijamco, J., Nguyen, N., Afshar, P.T., et al. (2018). A universal snp and small-indel variant
458 caller using deep neural networks. *Nat. Biotechnol.* *36*, 983.
- 459 15. AlDubayan, S.H., Conway, J.R., Camp, S.Y., Witkowski, L., Kofman, E., Reardon, B., Han,
460 S., Moore, N., Elmarakeby, H., Salari, K., et al. (2020). Detection of pathogenic variants with
461 germline genetic testing using deep learning vs standard methods in patients with prostate

- 462 cancer and melanoma. *JAMA - J. Am. Med. Assoc.* 324, 1957–1969.
- 463 16. Rahman, N. (2014). Realizing the promise of cancer predisposition genes. *Nature* 505, 302–
464 308.
- 465 17. Huang, K. lin, Mashl, R.J., Wu, Y., Ritter, D.I., Wang, J., Oh, C., Paczkowska, M., Reynolds,
466 S., Wyczalkowski, M.A., Oak, N., et al. (2018). Pathogenic Germline Variants in 10,389 Adult
467 Cancers. *Cell* 173, 355-370.e14.
- 468 18. Mirabello, L., Zhu, B., Koster, R., Karlins, E., Dean, M., Yeager, M., Gianferante, M.,
469 Spector, L.G., Morton, L.M., Karyadi, D., et al. (2020). Frequency of Pathogenic Germline
470 Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma. *JAMA Oncol.* 6, 724–
471 734.
- 472 19. Tate, J.G., Bamford, S., Jubb, H.C., Sondka, Z., Beare, D.M., Bindal, N., Boutselakis, H.,
473 Cole, C.G., Creatore, C., Dawson, E., et al. (2019). COSMIC: The Catalogue Of Somatic
474 Mutations In Cancer. *Nucleic Acids Res.* 47, D941–D947.
- 475 20. Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F., and Hamosh, A. (2015).
476 OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an Online catalog of human genes
477 and genetic disorders. *Nucleic Acids Res.* 43, D789–D798.
- 478 21. Jassal, B., Matthews, L., Viteri, G., Gong, C., Lorente, P., Fabregat, A., Sidiropoulos, K.,
479 Cook, J., Gillespie, M., Haw, R., et al. (2020). The reactome pathway knowledgebase. *Nucleic*
480 *Acids Res.* 48, D498–D503.
- 481 22. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde,
482 M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of
483 sequence variants: A joint consensus recommendation of the American College of Medical
484 Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* 17, 405–
485 424.
- 486 23. Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and
487 Mesirov, J.P. (2011). Integrative genomics viewer. *Nat. Biotechnol.* 29, 24–26.

- 488 24. Robinson, J.T., Thorvaldsdóttir, H., Wenger, A.M., Zehir, A., and Mesirov, J.P. (2017).
489 Variant review with the integrative genomics viewer. *Cancer Res.* 77, e31–e34.
- 490 25. Li, H., Sisoudiya, S.D., Martin-Giacalone, B.A., Khayat, M.M., Dugan-Perez, S., Marquez-
491 Do, D.A., Scheurer, M.E., Muzny, D., Boerwinkle, E., Gibbs, R.A., et al. (2020). Germline
492 Cancer Predisposition Variants in Pediatric Rhabdomyosarcoma: A Report From the Children’s
493 Oncology Group . *JNCI J. Natl. Cancer Inst.* 00, 1–9.
- 494 26. Gianferante, D.M., Mirabello, L., and Savage, S.A. (2017). Germline and somatic genetics of
495 osteosarcoma - Connecting aetiology, biology and therapy. *Nat. Rev. Endocrinol.* 13, 480–491.
- 496 27. Mirabello, L., Yu, K., Berndt, S.I., Burdett, L., Wang, Z., Chowdhury, S., Teshome, K.,
497 Uzoka, A., Hutchinson, A., Grotmol, T., et al. (2011). A comprehensive candidate gene
498 approach identifies genetic variation associated with osteosarcoma. *BMC Cancer* 11,.
499 28. Martin-Giacalone, B.A., Weinstein, P.A., Plon, S.E., and Lupo, P.J. (2021). Pediatric
500 Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility. *J. Clin. Med.* 10, 2028.
- 501 29. Zhang, J., Walsh, M.F., Wu, G., Edmonson, M.N., Gruber, T.A., Easton, J., Hedges, D., Ma,
502 X., Zhou, X., Yergeau, D.A., et al. (2015). Germline mutations in predisposition genes in
503 pediatric cancer. *N. Engl. J. Med.* 373, 2336–2346.
- 504 30. Kim, J., Light, N., Subasri, V., Young, E.L., Wegman-Ostrosky, T., Barkauskas, D.A., Hall,
505 D., Lupo, P.J., Patidar, R., Maese, L.D., et al. (2021). Pathogenic Germline Variants in Cancer
506 Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. *JCO Precis.*
507 *Oncol.* 75–87.
- 508 31. Naslund-Koch, C., Nordestgaard, B.G., and Bojesen, S.E. (2016). Increased risk for other
509 cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the
510 copenhagen general population study. *J. Clin. Oncol.* 34, 1208–1216.
- 511 32. Zou, X., Owusu, M., Harris, R., Jackson, S.P., Loizou, J.I., and Nik-Zainal, S. (2018).
512 Validating the concept of mutational signatures with isogenic cell models. *Nat. Commun.* 9, 1–
513 16.

- 514 33. Ba, W., Yan, Y., Reijnders, M.R.F., Schuurs-Hoeijmakers, J.H.M., Feenstra, I., Bongers,
515 E.M.H.F., Bosch, D.G.M., De Leeuw, N., Pfundt, R., Gilissen, C., et al. (2016). TRIO loss of
516 function is associated with mild intellectual disability and affects dendritic branching and
517 synapse function. *Hum. Mol. Genet.* 25, 892–902.
- 518 34. Jin, Z.B., Wu, J., Huang, X.F., Feng, C.Y., Cai, X.B., Mao, J.Y., Xiang, L., Wu, K.C., Xiao,
519 X., Kloss, B.A., et al. (2017). Trio-based exome sequencing arrests de novo mutations in early-
520 onset high myopia. *Proc. Natl. Acad. Sci. U. S. A.* 114, 4219–4224.
- 521 35. Samocha, K.E., Robinson, E.B., Sanders, S.J., Stevens, C., Sabo, A., McGrath, L.M.,
522 Kosmicki, J.A., Rehnström, K., Mallick, S., Kirby, A., et al. (2014). A framework for the
523 interpretation of de novo mutation in human disease. *Nat. Genet.* 46, 944–950.
- 524 36. Kratz, C.P., Freycon, C., Maxwell, K.N., Nichols, K.E., Schiffman, J.D., Evans, D.G., Achatz,
525 M.I., Savage, S.A., Weitzel, J.N., Garber, J.E., et al. (2021). Analysis of the Li-Fraumeni
526 Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency
527 for Research on Cancer TP53 Database Analysis. *JAMA Oncol.*
- 528 37. Collins, R.L., Brand, H., Karczewski, K.J., Zhao, X., Alföldi, J., Francioli, L.C., Khera, A. V.,
529 Lowther, C., Gauthier, L.D., Wang, H., et al. (2020). A structural variation reference for medical
530 and population genetics. *Nature* 581, 444–451.
- 531 38. Fahed, A.C., Wang, M., Homburger, J.R., Patel, A.P., Bick, A.G., Neben, C.L., Lai, C.,
532 Brockman, D., Philippakis, A., Ellinor, P.T., et al. (2020). Polygenic background modifies
533 penetrance of monogenic variants for tier 1 genomic conditions. *Nat. Commun.* 11, 1–9.
- 534 39. Wand, H., Lambert, S.A., Tamburro, C., Iacocca, M.A., O’Sullivan, J.W., Sillari, C., Kullo,
535 I.J., Rowley, R., Dron, J.S., Brockman, D., et al. (2021). Improving reporting standards for
536 polygenic scores in risk prediction studies. *Nature* 591, 211–219.
- 537 40. Sud, A., Turnbull, C., and Houlston, R. (2021). Will polygenic risk scores for cancer ever be
538 clinically useful? *Npj Precis. Oncol.* 5, 1–5.
- 539 41. Seplyarskiy, V.B., Soldatov, R.A., Koch, E., McGinty, R.J., Goldmann, J.M., Hernandez,

540 R.D., Barnes, K., Correa, A., Burchard, E.G., Ellinor, P.T., et al. (2021). Population sequencing
541 data reveal a compendium of mutational processes in the human germ line. *Science* (80-.).
542 eaba7408.

543 42. McLeod, C., Gout, A.M., Zhou, X., Thrasher, A., Rahbarinia, D., Brady, S.W., Macias, M.,
544 Birch, K., Finkelstein, D., Sunny, J., et al. (2021). St. Jude cloud: A pediatric cancer genomic
545 data-sharing ecosystem. *Cancer Discov.* *11*, 1082–1099.

546 43. Chen, X., Stewart, E., Shelat, A.A., Qu, C., Bahrami, A., Hatley, M., Wu, G., Bradley, C.,
547 McEvoy, J., Pappo, A., et al. (2013). Targeting Oxidative Stress in Embryonal
548 Rhabdomyosarcoma. *Cancer Cell* *24*, 710–724.

549 44. Downing, J.R., Wilson, R.K., Zhang, J., Mardis, E.R., Pui, C.H., Ding, L., Ley, T.J., and
550 Evans, W.E. (2012). The pediatric cancer genome project. *Nat. Genet.* *44*, 619–622.

551 45. Wang, Z., Wilson, C.L., Easton, J., Thrasher, A., Mulder, H., Liu, Q., Hedges, D.J., Wang,
552 S., Rusch, M.C., Edmonson, M.N., et al. (2018). Genetic risk for subsequent neoplasms among
553 long-term survivors of childhood cancer. *J. Clin. Oncol.* *36*, 2078–2087.

554 46. Robison, L.L., Mertens, A.C., Boice, J.D., Breslow, N.E., Donaldson, S.S., Green, D.M., Li,
555 F.P., Meadows, A.T., Mulvihill, J.J., Neglia, J.P., et al. (2002). Study design and cohort
556 characteristics of the Childhood Cancer Survivor Study: A multi-institutional collaborative
557 project. *Med. Pediatr. Oncol.* *38*, 229–239.

558 47. Mailman, M.D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., Hao, L., Kiang, A.,
559 Paschall, J., Phan, L., et al. (2007). The NCBI dbGaP database of genotypes and phenotypes.
560 *Nat. Genet.* *39*, 1181–1186.

561 48. Crompton, B.D., Stewart, C., Taylor-Weiner, A., Alexe, G., Kurek, K.C., Calicchio, M.L.,
562 Kiezun, A., Carter, S.L., Shukla, S.A., Mehta, S.S., et al. (2014). The Genomic Landscape of
563 Pediatric Ewing Sarcoma. *Cancer Discov.* *4*, 1326 LP – 1341.

564 49. Perry, J.A., Kiezun, A., Tonzi, P., Van Allen, E.M., Carter, S.L., Baca, S.C., Cowley, G.S.,
565 Bhatt, A.S., Rheinbay, E., Peadamallu, C.S., et al. (2014). Complementary genomic approaches

566 highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc. Natl.
567 Acad. Sci. 201419260.
568 50. Zhang, J., Bajari, R., Andric, D., Gerthoffert, F., Lepsa, A., Nahal-Bose, H., Stein, L.D., and
569 Ferretti, V. (2019). The International Cancer Genome Consortium Data Portal. Nat. Biotechnol.
570 37, 367–369.
571 51. Heath, A.P., Taylor, D.M., Zhu, Y., Raman, P., Lilly, J., Storm, P., Waanders, A.J., Ferretti,
572 V., Yung, C., Mattioni, M., et al. (2019). Abstract 2464: Gabriella Miller Kids First Data Resource
573 Center: Harmonizing clinical and genomic data to support childhood cancer and structural birth
574 defect research. Cancer Res. 79, 2464 LP – 2464.
575 52. Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Bentley, D.R., Chakravarti, A.,
576 Clark, A.G., Donnelly, P., Eichler, E.E., Flicek, P., et al. (2015). A global reference for human
577 genetic variation. Nature 526, 68–74.

578

579 **Figure Legends**

580 **Figure 1: Study overview and characteristics of discovery and validation cohorts.** A,
581 Study schematic overview. The discovery cohort comprised 1138 cases, and the enrichment of
582 pathogenic germline variants across 141 established cancer predisposition genes was
583 evaluated. Ancestry-matched case-control analyses were carried out across the pan-sarcoma
584 cohort (1138 cases), as well as major sarcoma histologic subtypes: osteosarcoma (436 cases),
585 rhabdomyosarcoma (180 cases), Ewing sarcoma (222 cases). The validation cohort comprised
586 433 cases of Ewing sarcoma. The enrichment of pathogenic germline variants in 43 DNA
587 damage repair genes was evaluated employing an ancestry-matched case-control analysis.
588 Mechanisms of inheritance were evaluated for 301 cases available as parent-proband trios. B,
589 Discovery cohort demographics: mean age 10.8 years, 52% male. C, Ewing sarcoma validation
590 cohort demographics: mean age 13.3 years, 54% male.


591 **Figure 2: Ancestry composition of discovery cohort. Enrichment of pathogenic germline**
592 **variants in discovery cohort, across and within major histologic subtypes.** A, Ancestry
593 composition of discovery cohort: 789 European cases (EUR), 136 African cases (AFR), 104
594 South Asian cases (SAS), 102 Admixed American cases (AMR), 7 East Asian cases (EAS). B –
595 D, Odds ratios and 95% confidence intervals for enrichment of pathogenic germline variants
596 among cancer predisposition genes. Red: Significant at FDR < 0.05 after Benjamini-Hochberg
597 procedure. Gray: Significant at $p < 0.05$, but does not meet FDR < 0.05. Genes with $p > 0.05$
598 are not displayed. B, Pan-sarcoma cohort (1138 cases, 5690 controls). C, Osteosarcoma
599 subset of cohort (436 cases, 3488 controls). D, Rhabdomyosarcoma subset of cohort (180
600 cases, 8280 controls). E, Ewing sarcoma subset of cohort (222 cases, 12654 controls).

601 **Figure 3: Enrichment of pathogenic germline variants in *FANCC* and other DNA damage**
602 **repair genes in Ewing sarcoma validation cohort.** A, Enrichment of pathogenic germline
603 variants in *FANCC* in the Ewing Sarcoma validation cohort vs. controls (OR 5.1, 95% CI 1.2 –
604 18.5). B, Enrichment of pathogenic germline variants in DNA damage response genes and
605 specific pathways (Red: Significant at $p < 0.05$; Gray: Not significant): 43 DNA damage
606 response genes (All DDR; OR 1.4, 95% CI 1.0 – 1.9, $p = 0.05$), 12 genes involved in DNA
607 double-strand break repair (DSB repair; OR 1.8, 95% CI 1.1 – 3.0, $p = 0.02$), 6 genes involved
608 in nucleotide excision repair (OR 2.8, 95% CI 1.2 – 5.9, $p = 0.01$), 16 genes involved in Fanconi
609 anemia pathway (OR 1.4, 95% CI 0.8 – 2.3, $p = 0.28$), 4 genes involved in mismatch repair
610 (MMR; OR 0.5, 95% CI 0 – 3.2, $p = 1.0$). C, Collective frequency of the 4 genes with enrichment
611 signal at $p < 0.05$ (*CHEK2*, *ERCC2*, *ERCC4*, and *FANCC*) in Ewing sarcoma cases vs. controls.
612 D, Rates of pathogenic variants in *TP53* in Ewing sarcoma validation cohort in comparison to
613 Ewing sarcoma subset of discovery cohort, rhabdomyosarcoma subset of discovery cohort,
614 osteosarcoma subset of discovery cohort, and pan-sarcoma discovery cohort (Fisher's exact
615 tests, n.s. denotes no significant difference, *** denotes significant difference at $p < 0.05$).


616 **Figure 4: Pathogenic germline variants in DNA damage repair genes are inherited in high-**
617 **risk families.** A, Pathogenic germline variants in DDR genes among trio probands with Ewing
618 sarcoma. 35 pathogenic variants impacting 32 of 301 patients with Ewing sarcoma were
619 identified. B, 32 of 32 probands (100%) with pathogenic germline variants in DDR genes had
620 identical variants identified in parents. 19 of 269 probands without a pathogenic germline variant
621 in a DDR gene had at least one parent with a germline DDR variant that was not inherited by
622 the proband (7.1%). C – D, Pedigrees and IGV screenshots of pathogenic variants in DDR
623 genes. Pedigree legend: circle = female sex, square = male sex, diamond = unknown sex, gray
624 shading = proband with Ewing sarcoma, * denotes variant 1 identified in parent-proband trio, ‡
625 denotes variant 2 identified in parent-proband trio. Top screenshot: Carrier Parent, Bottom
626 screenshot: Proband.
627

Figure 1

a)



b)



c)




Figure 2




Figure 3




Figure 4

